Chimeric Mouse Model for FSHD Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Facioscapulohumeral muscular dystrophy (FSHD) lacks effective treatments due to the absence of a recognized mouse model and the disease's variability and slow progression, making it difficult to establish therapeutic efficacy, and there is a need for molecular biomarkers to assess responsiveness to therapy.
Innovation Solution
The development of methods involving panels of biomarkers and chimeric animals to identify candidate compounds for FSHD treatment by measuring the expression of specific genes such as PRAMEF1, SLC34A2, TRIM49, and others, and using inhibitory nucleic acids to target these genes, along with cell lines and kits for drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical trials are conducted for FSHD treatment, then therapeutic efficacy can be evaluated, but the trials are discouraged due to the lack of a recognized mouse model and the disease's variability and slow progression
Solution Approach 1:
The patent creates chimeric mice that copy human FSHD pathology by introducing human muscle stem cells into mouse embryos. These chimeric mice replicate the disease characteristics of human FSHD patients, providing a reliable preclinical model for evaluating therapeutic efficacy without requiring direct human clinical trials to establish initial effectiveness.
Solution Approach 2:
The chimeric mouse serves as an intermediary model between human FSHD patients and potential therapies. It translates human disease pathology into a manageable animal model that can be used for drug screening and efficacy assessment, bridging the gap between basic research and clinical application.
2Measurement precision
If molecular biomarkers are developed for FSHD, then responsiveness to therapy can be assessed, but the disease's highly variable and slow progression makes establishing therapeutic efficacy difficult
Solution Approach 1:
The patent identifies and quantifies specific gene expression parameters (biomarkers) that change in response to FSHD pathology and therapy. By measuring expression levels of specific genes, the model enables precise assessment of therapeutic responsiveness and can detect treatment effects faster than waiting for clinical symptom improvement, which occurs slowly in human FSHD patients.
3Productivity
If a mouse model for FSHD is created, then drug screening can be facilitated, but the disease lacks a recognized mouse model
Solution Approach 1:
The patent performs preliminary actions by generating chimeric mice with human FSHD pathology before initiating drug screening programs. This pre-established model system enables high-throughput drug screening and efficacy assessment to proceed efficiently without the need to create new models for each study.
Solution Approach 2:
The chimeric mouse model serves multiple functions: it models human FSHD pathology, enables drug screening, allows biomarker validation, and provides a platform for mechanistic studies. This multi-functional model eliminates the need for separate systems for each research purpose, improving overall productivity.
Data Source
AI summary
Compositions and methods for identifying new treatments for Facioscapulohumeral muscular dystrophy (FSHD), and uses thereof.